Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development.
Harrington
K J
KJ
ICRF Oncology Unit, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London, UK. Harrington.Kevin@mayo.edu
Lewanski
C R
CR
Stewart
J S
JS
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000008:administration & dosage / Q000493:pharmacokinetics; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin; D002945:Cisplatin; D003630:Daunorubicin